EGFR基因突变与晚期肺腺癌一线化疗疗效的相关性分析
Correlation analysis between EGFR gene mutation and the ef- ficacy of first-line chemotherapy for advanced lung adenocar- cinoma
杨宝军 1张芳 1王飞亚1
作者信息
- 1. 467000(河南·平顶山)平顶山市平煤神马医疗集团总医院
- 折叠
摘要
目的 探讨表皮生长因子受体基因突变与晚期肺腺癌患者一线化疗疗效的相关性.方法 对234例晚期肺腺癌患者均行培美曲塞联合铂类(顺铂或卡铂)化疗,每21 d为1个周期,治疗2个周期参照实体瘤疗效评价标准判定近期临床疗效.研究结束时(2017年12月31日) ,统计客观有效率、疾病控制率、无疾病进展生存期,并分析表皮生长因子受体基因突变与化疗疗效的关系.结果 (1)本组患者表皮生长因子受体基因为突变型92例(39 .3%) ,野生型142例(60 .7%) ;接受一线化疗方案后客观有效率为24 .2%,疾病控制率为75 .8%,无疾病进展生存期为4 .5个月. (2 )接受一线化疗方案后,表皮生长因子受体基因突变型患者的疾病控制率(83 .7%)高于野生型患者(69 .7%) ,无疾病进展生存期(6 .2个月)长于野生型患者(3 .9个月) ,差异有统计学意义(P＜0 .05) . (3)多因素分析显示,表皮生长因子受体基因突变是晚期肺腺癌患者化疗无疾病进展生存期的独立预测因素(P＜0 .05).结论 表皮生长因子受体基因突变对晚期肺腺癌患者一线化疗疗效有独立预测价值.
Abstract
( Pingdingshan Ping m ei Shenm a Medical Group General Hospital , Pingdingshan 467000 , Henan ,China)[Abstract]Objective To investigate the correlation between EGFR gene mutation and the efficacy of first- line chemotherapy for advanced lung adenocarcinoma .Methods All 234 patients with advanced lung ade- nocarcino ma received pemetrexed plus platinum (cisplatin or carboplatin ) chemotherapy ,every 21 days for 1 cycle.Af ter 2 cycles of treatment , the short-term clinical efficacy w as determined by reference to the RECIS T 1 .1 .A t the end of the study (Decem ber 31 ,2017 ) ,analyze objective efficiency ,disease control rate ,disease-free survival , and analyze the relationship betw een epidermal g row th factor receptor gene mutation and chemotherapy efficacy .Results (1) In this group of patients ,92casess (39 .3%) were EG- FR m utation ,and 142 cases (60 .7%) w ere w ild type .Af ter receiving the first-line chemotherapy regi- men ,the objective effective rate was 24 .2%,the disease control rate was 75 .8%,and the disease-free sur- vival period w as 4 .5 months .(2 ) After first-line chemotherapy regimen ,the disease control rate of pa- tients w ith EGFR mutations (83 .7%) w as higher than that of w ild-type patients (69 .7%) ,and the pro- g ression-free survival (6 .2 months) w as longer than that of w ild-type patients (3 .9 months).T he differ- ence w as statistically significant ( P＜0 .05).(3) M ultivariate analysis show ed that epidermal grow th fac- tor receptor w as an independent predictor of prog ression-free survival in patients w ith advanced lung ade- nocarcino ma ( P＜0 .05).Conclusion Epidermal grow th factor receptor mutation has independent predic- tive value for first-line chemotherapy in patients w ith advanced lung adenocarcino ma .
关键词
晚期肺腺癌/表皮生长因子受体/一线化疗/无疾病进展生存期/疗效Key words
Advanced lung adenocarcinoma/epidermal growth factor receptor/first-line chemotherapy/disease-free survival/efficacy引用本文复制引用
出版年
2019
NETL
NSTL
维普
万方数据